GO
Loading...

Baxter International Inc

More

  • Midday Glance: Medical Devices companies Monday, 13 Oct 2014 | 1:19 PM ET

    Allergan fell $2.27 or 1.2 percent, to $185.35. Baxter International Inc. fell$. 52 or. 7 percent, to $70.73. Boston Scientific Corp. rose$. 08 or. 6 percent, to $12.00.

  • Early Glance: Medical Devices companies Monday, 13 Oct 2014 | 10:30 AM ET

    Allergan fell $1.25 or. 7 percent, to $186.36. Baxter International Inc. fell$. 38 or. 5 percent, to $70.87. Boston Scientific Corp. rose$. 05 or. 4 percent, to $11.97.

  • Early Glance: Pharmaceuticals companies Monday, 13 Oct 2014 | 10:30 AM ET

    Baxter International Inc. fell$. 38 or. 5 percent, to $70.87. Bristol-Myers Squibb Co. fell$. 12 or. 2 percent, to $50.16. Hospira fell$. 30 or. 6 percent, to $49.87.

  • Midday Glance: Medical Devices companies Friday, 10 Oct 2014 | 1:19 PM ET

    Allergan rose $1.84 or 1.0 percent, to $189.39. Baxter International Inc. fell$. 04 or. 1 percent, to $71.77. Boston Scientific Corp. rose$. 19 or 1.6 percent, to $12.11.

  • Midday Glance: Pharmaceuticals companies Friday, 10 Oct 2014 | 1:19 PM ET

    Baxter International Inc. fell$. 04 or. 1 percent, to $71.77. Bristol-Myers Squibb Co. rose $1.21 or 2.5 percent, to $50.71. Hospira fell$. 22 or. 4 percent, to $50.82.

  • Early Glance: Pharmaceuticals companies Friday, 10 Oct 2014 | 10:28 AM ET

    Baxter International Inc. rose$. 20 or. 3 percent, to $72.01. Bristol-Myers Squibb Co. rose$. 94 or 1.9 percent, to $50.44. Pfizer rose$. 20 or. 7 percent, to $29.19.

  • Early Glance: Medical Devices companies Friday, 10 Oct 2014 | 10:28 AM ET

    Allergan rose $1.45 or. 8 percent, to $189.00. Baxter International Inc. rose$. 20 or. 3 percent, to $72.01. Boston Scientific Corp. rose$. 14 or 1.2 percent, to $12.06.

  • Final Glance: Medical Devices companies Thursday, 9 Oct 2014 | 6:01 PM ET

    Allergan fell $2.95 or 1.5 percent, to $187.55. Baxter International Inc. fell $1.36 or 1.9 percent, to $71.81. Boston Scientific Corp. fell$. 22 or 1.8 percent, to $11.92.

  • Final Glance: Pharmaceuticals companies Thursday, 9 Oct 2014 | 6:01 PM ET

    Baxter International Inc. fell $1.36 or 1.9 percent, to $71.81. Bristol-Myers Squibb Co. fell$. 71 or 1.4 percent, to $49.50. Hospira fell $1.43 or 2.7 percent, to $51.03.

  • Midday Glance: Medical Devices companies Thursday, 9 Oct 2014 | 2:06 PM ET

    Allergan fell$. 52 or. 3 percent, to $189.98. Baxter International Inc. fell $1.08 or 1.5 percent, to $72.09. Boston Scientific Corp. fell$. 18 or 1.5 percent, to $11.96.

  • Midday Glance: Pharmaceuticals companies Thursday, 9 Oct 2014 | 2:06 PM ET

    Baxter International Inc. fell $1.08 or 1.5 percent, to $72.09. Bristol-Myers Squibb Co. fell$. 48 or 1.0 percent, to $49.73. Hospira fell $1.18 or 2.2 percent, to $51.28.

  • Early Glance: Pharmaceuticals companies Thursday, 9 Oct 2014 | 11:31 AM ET

    Baxter International Inc. fell$. 07 or. 1 percent, to $73.10. Bristol-Myers Squibb Co. rose$. 12 or. 2 percent, to $50.33. Hospira fell$. 48 or. 9 percent, to $51.98.

  • Early Glance: Medical Devices companies Thursday, 9 Oct 2014 | 11:31 AM ET

    Allergan rose $1.76 or. 9 percent, to $192.26. Baxter International Inc. fell$. 07 or. 1 percent, to $73.10. Boston Scientific Corp. fell$. 09 or. 7 percent, to $12.06.

  • Providing support was a renewed pledge by European Central Bank President Mario Draghi to keep monetary policy loose for an extended period to push inflation in the euro zone closer to the targeted two percent level.

  • Sept 24- Drug developer Merrimack Pharmaceuticals Inc said it would partner with Baxter International Inc to develop and market its pancreatic cancer drug outside the United States, sending its shares up as much as 27 percent premarket.

  • Providing support was a renewed pledge by European Central Bank President Mario Draghi to keep monetary policy loose for an extended period to push inflation in the euro zone closer to the targeted two percent level.

  • NEW YORK, Sept 24- Merrimack Pharmaceuticals shares were surging in premarket trade, up 24.5 percent to $8.95 after the company said it reached a deal to develop and market Merrimack's pancreatic cancer drug outside the U.S. with Baxter International.

  • Baxter to market Merrimack's cancer drug outside U.S. Wednesday, 24 Sep 2014 | 8:08 AM ET

    Sept 24- Drug developer Merrimack Pharmaceuticals Inc said it would partner with Baxter International Inc to develop and market its pancreatic cancer drug outside the United States, sending its shares up as much as 27 percent premarket.

  • Aug 21- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

  • US labs on standby to start work on Ebola drug Sunday, 10 Aug 2014 | 6:02 AM ET
    A nurse wears protective clothing as he demonstrates the facilities in place at the Royal Free Hospital in north London on August 6, 2014, in preparation for a patient testing positive for the Ebola virus.

    All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.